2023-04-24-上交所-健康元药业集团股份有限公司2023年第一季度报告（英文版）_12页_293kb

报告摘要

Revenue: Decreased by 2.11% year-over-year to RMB 4,559,049,786.82.
Net Profit Attributable to Shareholders: Increased by 0.48% to RMB 462,746,183.03.
Net Profit After Extraordinary Items: Decreased by 2.28% to RMB 446,772,473.94.
Operating Cash Flow: Dropped by 71.55% to RMB 248,084,750.71.
Key Ratios: Basic earnings per share (EPS) was RMB 0.2404 (-0.31% YoY), weighted average return on net assets decreased by 0.35 percentage points to 3.49%.

Chemical Pharmaceuticals: Revenue fell 16.09% YoY, with respiratory formulation products (+41.18%) leading the decline in segments like gastroenterology (-25.23%) and gonadotropic hormones (-21.60%).
APIs and Intermediates: Revenue increased 3.44% YoY to RMB 1,454 million.
Traditional Chinese Medicine Products: Revenue surged 100.68% YoY to RMB 567 million.
Overall, diversification supported growth, with biological products (+12.22%) and health care products (+46.99%) contributing positively.

Minor net gain of RMB 15,973,709.09, driven by government grants (+51 million) and offset by fair value changes (-18.24 million), after tax adjustments.

Total ordinary shares held: 87,173 million, with top 10 shareholders including Shenzhen Baiyeyuan Investment Co., Ltd. (46.43% stake, pledged shares), Hong Kong Securities Clearing Company Limited, Might Seasons Limited, and others. No major connections or acting-in-concert relationships reported.

Operating Cash Flow Decline: Primarily due to increased raw material procurement costs and reduced revenue collections.
Other Changes: Factors included foreign exchange losses, bonus payments, and equity investment fair value adjustments.